Cargando…

Cost-utility of Protocols of BFM-ALL and UK-ALL for Treatment of Children with Acute Lymphoblastic Leukemia in Iran

BACKGROUND: There is a requirement to assess the effectiveness and resources used in two protocols United Kingdom (UK-ALL) and Berlin-Frankfurt-Munster (BFM-ALL) that are most commonly used to treatment of ALL patients by oncologists in Iran. Accordingly, we analyzed the cost of treatment and utilit...

Descripción completa

Detalles Bibliográficos
Autores principales:	HAYATI, Hadi, KEBRIAEEZADEH, Abbas, EHSANI, Mohammad Ali, NIKFAR, Shekoufeh, AKBARI SARI, Ali, MEHRVAR, Azim, SHAHGHOLI, Elham
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971178/ https://www.ncbi.nlm.nih.gov/pubmed/29845029

Ejemplares similares

Direct and indirect cost of managing Alzheimer’s disease in the Islamic Republic of Iran
por: Aajami, Zahra, et al.
Publicado: (2019)

Outcome of ALL With ALL-BFM-95 Protocol in Nepal
por: Sharma Poudyal, Bishesh, et al.
Publicado: (2023)

Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran
por: Keshavarz, Khosro, et al.
Publicado: (2015)

Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran
por: Nikfar, Shekoufeh, et al.
Publicado: (2005)

Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments
por: Nikfar, Shekoufeh, et al.
Publicado: (2013)

Pharmacists Remuneration Models in Iran and Selected Countries: a Comparative Study
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2013)

Trend analysis of the pharmaceutical market in Iran; 1997–2010; policy implications for developing countries
por: Kebriaeezadeh, Abbas, et al.
Publicado: (2013)

Cost analysis of childhood asthma in Iran: A cost evaluation based on referral center data for asthma and allergies
por: Rezvanfar, Mohammad Ali, et al.
Publicado: (2013)

Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia
por: Schieck, Maximilian, et al.
Publicado: (2020)

A Cost-Utility and Cost-Effectiveness Analysis of Different Oral Antiviral Medications in Patients With HBeAg-Negative Chronic Hepatitis B in Iran: An Economic Microsimulation Decision Model
por: Keshavarz, Khosro, et al.
Publicado: (2016)

The impact of donor type on the outcome of pediatric patients with very high risk acute lymphoblastic leukemia. A study of the ALL SCT 2003 BFM-SG and 2007-BFM-International SG
por: Dalle, Jean-Hugues, et al.
Publicado: (2020)

Financial perspective of private pharmacies in Tehran (Iran); is it a lucrative business?
por: Keshavarz, Khosro, et al.
Publicado: (2012)

Assessment of the vaccine industry in Iran in context of accession to WTO: a survey study
por: Hashemi Meshkini, Amir, et al.
Publicado: (2012)

Budget impact analysis of vaccination against Haemophilus influenzae type b as a part of a Pentavalent vaccine in the childhood immunization schedule of Iran
por: Teimouri, Fatemeh, et al.
Publicado: (2017)

Commercialization of biopharmaceutical knowledge in Iran; challenges and solutions
por: Nassiri-Koopaei, Nasser, et al.
Publicado: (2014)

Go with the Flow—Early Assessment of Measurable Residual Disease in Children with Acute Lymphoblastic Leukemia Treated According to ALL IC-BFM2009
por: Pawinska-Wasikowska, Katarzyna, et al.
Publicado: (2022)

Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study
por: Rizzari, Carmelo, et al.
Publicado: (2019)

Chemotherapy-related hyperbilirubinemia in pediatric acute lymphoblastic leukemia: a genome-wide association study from the AIEOP-BFM ALL study group
por: Junk, Stefanie V., et al.
Publicado: (2023)

Pharmacogenomics Implementation and Hurdles to Overcome; In the Context of a Developing Country
por: Ayati, Nayyereh, et al.
Publicado: (2021)

PB1747: OUTCOME OF CHILDHOOD ALLTREATED WITH ALL BFM IC 2009 PROTOCOL
por: Çilsaat, Gizem, et al.
Publicado: (2023)

Invasive fungal diseases impact on outcome of childhood ALL – an analysis of the international trial AIEOP-BFM ALL 2009
por: Lehrnbecher, Thomas, et al.
Publicado: (2022)

Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol
por: Rizzari, Carmelo, et al.
Publicado: (2023)

A model for developing a decision support system to simulate national drug policy indicators
por: Abdollahiasl, Akbar, et al.
Publicado: (2011)

Cost-effectiveness of adding-on new antiepileptic drugs to conventional regimens in controlling intractable seizures in children
por: Gharibnaseri, Zahra, et al.
Publicado: (2012)

Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen
por: Kroll, Mirko, et al.
Publicado: (2020)

Second malignant neoplasms after treatment of 1487 children and adolescents with acute lymphoblastic leukemia—A population‐based analysis of the Austrian ALL‐BFM Study Group
por: Poyer, Fiona, et al.
Publicado: (2022)

The Prognostic Effect of CDKN2A/2B Gene Deletions in Pediatric Acute Lymphoblastic Leukemia (ALL): Independent Prognostic Significance in BFM-Based Protocols
por: Ampatzidou, Mirella, et al.
Publicado: (2023)

A Systematic Review of Discrete Choice Experiment Studies in Rheumatoid Arthritis Biological Medicines
por: Zartab, Saman, et al.
Publicado: (2021)

Consistent defined threshold and equity in health
por: Nikfar, Shekoufeh, et al.
Publicado: (2015)

Hypersensitivity Reactions to Native E. coli L-asparaginase in Children With Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction
por: Möricke, Anja, et al.
Publicado: (2023)

A systematic cost-effectiveness analysis of pregabalin in the management of fibromyalgia: an Iranian experience
por: Keshavarz, Khosro, et al.
Publicado: (2013)

A Scoping Review of Different Methods of Assessing the Impact of New Medical Technologies at Early Stages of Development
por: Goudarzi, Zahra, et al.
Publicado: (2021)

Day 15 and Day 33 Minimal Residual Disease Assessment for Acute Lymphoblastic Leukemia Patients Treated According to the BFM ALL IC 2009 Protocol: Single-Center Experience of 133 Cases
por: Radu, Letitia-Elena, et al.
Publicado: (2020)

Long‐term treatment results of Polish pediatric and adolescent patients enrolled in the ALL IC‐BFM 2002 trial
por: Kowalczyk, Jerzy R., et al.
Publicado: (2019)

Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2013)

A system dynamics model for national drug policy
por: Abdollahiasl, Akbar, et al.
Publicado: (2014)

A review on inputs and outputs in determining the efficiency of universities of medical sciences by data envelopment analysis method
por: Mojahedian, Mohammad M., et al.
Publicado: (2020)

PB1733: LONG-TERM FOLLOW-UP FOR PATIENTS WITH T CELL LYMPHOBLASTIC LYMPHOMA/ ACUTE LYMPHOBLASTIC LEUKEMIA WHO RECEIVED MODIFIED BFM PROTOCOLS
por: Gao, Yan, et al.
Publicado: (2023)

PEG-asparaginase in BFM-90 regimen improves outcomes in adults with newly diagnosed lymphoblastic lymphoma
por: Zheng, Wen, et al.
Publicado: (2017)

From generic scheme to brand-generic scheme: Have new policy influenced the efficiency of Iranian pharmaceutical companies?
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2niuol2ge7ffjp36it2uj2em3i